The mission of St. Jude Children's Research Hospital is to find cures for children with catastrophic illnesses through research and treatment. The resources of the hospital have been focused on pediatric cancer throughout its 44 year history and the Cancer Center has been supported by a CCSG for 29 years. Through the support of the American Lebanese Syrian Associated Charities (ALSAC), a separate corporation whose only purpose is to raise money in support of St. Jude Children's Research Hospital, patients are accepted without regard to ability to pay. Public support of the hospital through ALSAC provides a strong foundation for our Cancer Center upon which extramurally funded research and CCSG support can be leveraged to their fullest potential. In the current application, six multidisciplinary research programs are described. The Molecular Oncology (MO) and Signal Transduction (ST) Programs focus on basic, discovery-oriented research. The Developmental Therapeutics for Solid Malignancies (DTSM), Hematologic Malignancies (HM), Neurobiology and Brain Tumor (NBT), and Cancer Prevention and Control (CPC) Programs emphasize the translation of laboratory or population science to clinical application. The latter program is new to this application and represents the culmination of a long-standing commitment to long-term follow-up of our patient population, a recent commitment to population sciences, and successful recruitment of a world-class scientist to lead efforts in this area. Research by the 139 members of the Cancer Center is supported by 12 Shared Resources and an outstanding clinical research infrastructure. During the previous funding period, a new Cancer Center Director was appointed and the overall structure of our Cancer Center and its leadership were enhanced by several organizational changes, including bringing the infrastructure supporting the expansive clinical trials efforts administratively under the Cancer Center's authority. Several Program leader changes and the successful recruitment of three new outstanding Department Chairs (Immunology, Chemical Biology, and Epidemiology/Cancer Control) during the last funding period significantly enhance the multidisciplinary science done by our Cancer Center Programs. St. Jude Cancer Center investigators had over 2000 cancer-related publications during the funding period, 20% of which represented intraprogrammatic interactions and 15% of which were inter-programmatic. Extramural support for cancer research done at St. Jude is currently over $50 million per year, $31 million of which is from the NCI/HHMI. St. Jude Children's Research Hospital recently went through a vigorous Strategic Planning process and made a strong and long-term commitment to remain focused on cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA021765-32S1
Application #
8023242
Study Section
Special Emphasis Panel (ZCA1-RTRB-Z (O1))
Program Officer
Ogunbiyi, Peter
Project Start
1997-04-01
Project End
2013-02-28
Budget Start
2010-03-01
Budget End
2011-02-28
Support Year
32
Fiscal Year
2010
Total Cost
$126,000
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Mueller, Emily L; Park, Elyse R; Kirchhoff, Anne C et al. (2018) Insurance, chronic health conditions, and utilization of primary and specialty outpatient services: a Childhood Cancer Survivor Study report. J Cancer Surviv 12:639-646
Perez, Giselle K; Kirchhoff, Anne C; Recklitis, Christopher et al. (2018) Mental health insurance access and utilization among childhood cancer survivors: a report from the childhood cancer survivor study. J Cancer Surviv 12:528-536
Oladimeji, Peter O; Chen, Taosheng (2018) PXR: More Than Just a Master Xenobiotic Receptor. Mol Pharmacol 93:119-127
Wilson, Carmen L; Howell, Carrie R; Partin, Robyn E et al. (2018) Influence of fitness on health status among survivors of acute lymphoblastic leukemia. Pediatr Blood Cancer 65:e27286
Weil, Brent R; Madenci, Arin L; Liu, Qi et al. (2018) Late Infection-Related Mortality in Asplenic Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol 36:1571-1578
Wong, Timothy; Wang, Zhican; Chapron, Brian D et al. (2018) Polymorphic Human Sulfotransferase 2A1 Mediates the Formation of 25-Hydroxyvitamin D3-3-O-Sulfate, a Major Circulating Vitamin D Metabolite in Humans. Drug Metab Dispos 46:367-379
Triplett, Brandon M; Muller, Brad; Kang, Guolian et al. (2018) Selective T-cell depletion targeting CD45RA reduces viremia and enhances early T-cell recovery compared with CD3-targeted T-cell depletion. Transpl Infect Dis 20:
Crawford, Rebecca R; Potukuchi, Praveen K; Schuetz, Erin G et al. (2018) Beyond Competitive Inhibition: Regulation of ABC Transporters by Kinases and Protein-Protein Interactions as Potential Mechanisms of Drug-Drug Interactions. Drug Metab Dispos 46:567-580
Rong, Yongqi; Bansal, Parmil K; Wei, Peng et al. (2018) Glycosylation of Cblns attenuates their receptor binding. Brain Res 1694:129-139
Levine, Jennifer M; Whitton, John A; Ginsberg, Jill P et al. (2018) Nonsurgical premature menopause and reproductive implications in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer 124:1044-1052

Showing the most recent 10 out of 6764 publications